As of November 10, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Enliven Therapeutics Inc. The largest reported stake is Fmr LLC's, at 15%. 18 filings are on record since July 17, 2025 (Schedule 13G/A, August 6, 2026).
Who owns Enliven Therapeutics, Inc.?
Sell to companies like Enliven Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: BlackRock, Inc. · Sole voting: 5,097,086 · Shared voting: 0 · Sole dispositive: 5,206,581 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-27
- · Reporting person: Fmr LLC · Sole voting: 10,704,808 · Shared voting: 0 · Sole dispositive: 10,713,540 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-06
- · Reporting person: Orbimed Advisors LLC · Sole voting: 0 · Shared voting: 6,774,507 · Sole dispositive: 0 · Shared dispositive: 6,774,507 · SCHEDULE 13D/A, 2026-06-24
- · Reporting person: Polar Capital Holdings Plc · Sole voting: 5,056,807 · Shared voting: 0 · Sole dispositive: 5,056,807 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-06-22
- · Holder: Orbimed Advisors LLC · Percent: 10.93% · SCHEDULE 13D/A
Enliven Therapeutics Inc has 18 Schedule 13D or 13G filings on record since 2025-07-17. 6 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fmr LLC | 15% | 10,713,540 | SCHEDULE 13G/A, 2026-08-06 | 2026-06-30 |
| Orbimed Advisors LLC | 9.5% | 6,774,507 | SCHEDULE 13D/A, 2026-06-24 | 2026-06-22 |
| Polar Capital Holdings Plc | 8.46% | 5,056,807 | SCHEDULE 13G/A, 2026-06-22 | 2026-03-31 |
| Commodore Capital LP | 7.7% | 4,800,940 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| BlackRock, Inc. | 7.1% | 5,206,581 | SCHEDULE 13G/A, 2026-10-27 | 2026-09-30 |
| Vestal Point Capital, LP | 5.4% | 3,250,000 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Fairmount Funds Management LLC | 3.1% | 1,855,644 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Venrock Healthcare Capital Partners III, L.P. | 2.8% | 1,726,331 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
Holding shares or following this stake? See who's behind Enliven Therapeutics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Enliven Therapeutics Inc and the records around it.
Enliven Therapeutics Inc elsewhere on the record
- Leadership changes Oct 2026
- Who owns it
Companies that share a holder
- Polar Capital Holdings Plc also filed stake reports on 3 other companies: Arcutis Biotherapeutics, Inc. (Aug 2026), Verastem, Inc. (Jul 2026), HAGERTY, INC. (Sep 2025)
- Fairmount Funds Management LLC also filed stake reports on 13 other companies: Alaunos Therapeutics, Inc. (Oct 2026), SPYRE THERAPEUTICS, INC. (Oct 2026), Korsana Biosciences, Inc. (Sep 2026)
- Vestal Point Capital, LP also filed stake reports on 27 other companies: Alto Neuroscience, Inc. (Aug 2026), iBio, Inc. (Aug 2026), Immunocore Holdings plc (Aug 2026)
Watch Enliven Therapeutics Inc
Get an email when Enliven Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Enliven Therapeutics Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Enliven Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Enliven Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fmr LLC | 10,704,808 | 0 | 10,713,540 | 0 | SCHEDULE 13G/A, 2026-08-06 |
| Abigail P. Johnson | 0 | 0 | 10,713,540 | 0 | SCHEDULE 13G/A, 2026-08-06 |
| Orbimed Advisors LLC | 0 | 6,774,507 | 0 | 6,774,507 | SCHEDULE 13D/A, 2026-06-24 |
| Orbimed Capital Gp Vii LLC | 0 | 6,555,102 | 0 | 6,555,102 | SCHEDULE 13D/A, 2026-06-24 |
| Orbimed Genesis Gp LLC | 0 | 219,405 | 0 | 219,405 | SCHEDULE 13D/A, 2026-06-24 |
| Orbimed Capital LLC | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-06-24 |
| Polar Capital Holdings Plc | 5,056,807 | 0 | 5,056,807 | 0 | SCHEDULE 13G/A, 2026-06-22 |
| Polar Capital LLP | 5,056,807 | 0 | 5,056,807 | 0 | SCHEDULE 13G/A, 2026-06-22 |
| Polar Capital Funds PLC - Biotechnology Fund | 5,056,807 | 0 | 5,056,807 | 0 | SCHEDULE 13G/A, 2026-06-22 |
| BlackRock, Inc. | 5,097,086 | 0 | 5,206,581 | 0 | SCHEDULE 13G/A, 2026-10-27 |
The latest filing identifies Enliven Therapeutics Inc by CUSIP 29337E102 and gives its principal executive office as 205 Park Road, Burlingame, CA 94010 (SCHEDULE 13G/A, 2026-10-27).
Source of funds (Item 3)
Not applicable.Orbimed Advisors LLC, SCHEDULE 13D/A, 2026-06-24
Purpose of Transaction (Item 4)
Orbimed Advisors LLC
The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-06-24; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | BlackRock, Inc. | 5.1% | SCHEDULE 13G/A |
| 2025-08-14 | Fairmount Funds Management LLC | 6.3% | SCHEDULE 13G/A |
| 2025-08-14 | Polar Capital Holdings Plc | 5.17% | SCHEDULE 13G |
| 2025-08-14 | Commodore Capital LP | 9.9% | SCHEDULE 13G/A |
| 2025-11-05 | Fmr LLC | 13.3% | SCHEDULE 13G/A |
| 2025-11-14 | Venrock Healthcare Capital Partners III, L.P. | 5.4% | SCHEDULE 13G/A |
| 2026-02-17 | Vestal Point Capital, LP | 6.5% | SCHEDULE 13G |
| 2026-05-15 | Vestal Point Capital, LP | 5.4% | SCHEDULE 13G/A |
| 2026-05-15 | Fairmount Funds Management LLC | 3.1% | SCHEDULE 13G/A |
| 2026-05-15 | Polar Capital Holdings Plc | 8.47% | SCHEDULE 13G/A |
| 2026-05-15 | Polar Capital Holdings Plc | 8.46% | SCHEDULE 13G/A |
| 2026-05-15 | Venrock Healthcare Capital Partners III, L.P. | 2.8% | SCHEDULE 13G/A |
| 2026-05-15 | Commodore Capital LP | 7.7% | SCHEDULE 13G/A |
| 2026-06-17 | Orbimed Advisors LLC | 10.93% | SCHEDULE 13D/A |
| 2026-06-22 | Polar Capital Holdings Plc | 8.46% | SCHEDULE 13G/A |
| 2026-06-24 | Orbimed Advisors LLC | 9.5% | SCHEDULE 13D/A |
| 2026-08-06 | Fmr LLC | 15% | SCHEDULE 13G/A |
| 2026-10-27 | BlackRock, Inc. | 7.1% | SCHEDULE 13G/A |
Questions about who owns Enliven Therapeutics Inc
Who owns Enliven Therapeutics Inc?
On this page, 6 holders' latest ownership filings report 5% or more of Enliven Therapeutics Inc: Fmr LLC (15%, Schedule 13G/A, filed 2026-08-06), Orbimed Advisors LLC (9.5%, Schedule 13D/A, filed 2026-06-24), Polar Capital Holdings Plc (8.46%, Schedule 13G/A, filed 2026-06-22), Commodore Capital LP (7.7%, Schedule 13G/A, filed 2026-05-15) and BlackRock, Inc. (7.1%, Schedule 13G/A, filed 2026-10-27); 1 more is listed above.
Who are the largest shareholders of Enliven Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Enliven Therapeutics Inc on this page are Fmr LLC (15%), Orbimed Advisors LLC (9.5%) and Polar Capital Holdings Plc (8.46%).
When did Fmr LLC buy into Enliven Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G/A, filed 2025-11-05, reporting 13.3%; its latest, Schedule 13G/A filed 2026-08-06, reports 15%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 18 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Enliven Therapeutics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 14, 2026 | Leadership change: Kristine Ball appointed, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Enliven Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.